The patients studied were nine males and seven females, gallbladder wall was cut off. All of the specimens were frozen at -20°C until assayed.
Ten days after the surgery, in the three patients with an indwelling T-tube, the concentration of ceftazidime in blood and bile after i.v. injection of 1-g doses was determined hourly. Blood and T-tube bile samples were collected several times at 1-h intervals after administration. All of these 73.4 ± 4.9 36.1 ± 2.2 24.9 ± 2.0 17.8 ± 1.5 13.0 ± 1.6 3.9 ± 1.1 31.8 ± 3.7 9.1 ± 1.6 a M, male; F, female. ranging in age from 34 to 72 years (mean, 54.5 years); 13 had cholelithiasis and 3 had choledocholithiasis. To 13 patients who underwent cholecystectomy, 1 g of ceftazidime dissolved in 20 ml of saline was given intravenously (i.v.) over a 3-min period before the operation. Blood samples were collected from the peripheral vein 5, 60, 120, 180, and 240 min after administration. Serum was separated immediately and kept at -20°C. At the time of cholecystectomy, 60 min after administration of ceftazidime, a narrow-diameter tube Was inserted into the cystic duct. Then the cystic duct was ligated before collection of the common duct bile to prevent transfer between common duct bile and gallbladder bile. Gallbladder bile was collected from these patients by puncturing the gallbladder wall, and in the other three patients it was collected from the removed gallbladder. In the removed gallbladders, blood and bile adhering to the surface were removed with sterile gauze, and about 1.5 cm2 of the * Corresponding author.
specimens were stored at -20°C.
The concentration of ceftazidime was determined by a bioassay, with Proteus mirabilis ATCC 21100 as the test organism.
Ceftazidime concentrations in serum, bile, and gallbladder wall are shown in Tables 1 and 2 . In the 13 patients who underwent cholecystectomy, the mean serum concentration after an i.v. injection remained relatively high even after 240 min.
The concentrations in the gallbladder bile could be determined in 12 patients and ranged widely, from 0.1 to 15.2 p,g/ml. In patients 5, 7, and 12, in whom the cystic duct was obstructed by inflammation or gall stones, the concentrations were very low. The highest concentration observed (patient 1, no obstruction of the cystic duct) was 15.2 ,ug/ml.
Concentrations in the common duct bile could be determined in 13 patients. The maximum concentration seen was 55. 4 ,ug/ml in patient 5 with normal liver function. Despite minor liver function disorders, in patients 4, 7, and 11, the concentrations were relatively high. Concentrations in the gallbladder tissues tended to be lower in chronic cholecystitis cases with more severe fibrous and inflammatory change in the gallbladder wall. Concentrations in common duct bile in three patients with T-tube drainage at the time of surgery reached peak levels 180 min after i.v. administration, with little change even after 360 min.
Neither adverse effects nor abnormal laboratory findings related to the drug were observed during the study period.
The present results revealed that the concentration of ceftazidime in serum reached a peak 5 min after i.v. bolus injection. Although the value was lower than the 105.6 Fg/ml reported by Harding et al. (2) , a concentration in serum of 13.0 ± 1.6 ,ug/ml was seen even 240 min later. Patients with cystic duct obstruction had only a small amount of ceftazidime in the gallbladder. Although high ceftazidime concentrations were observed in the common duct bile, these were similar to the levels in serum determined at the same time. Our study suggested no abnormal excretion into common duct bile in patients with minor liver function disorders. In patients with a T-tube for drainage, the peak biliary levels of ceftazidime were seen 180 min after administration and an effective concentration remained for a relatively long time. Tanimura et al. gave 1 g of ceftazidime i.v. to patients with T-tube drainage and reported a peak biliary level of ceftazidime of 46.7 p,g/ml, of which 63 to 96% remained after 6 h (3).
Based on the above results and other reports, ceftazidime is considered to be a useful drug for the therapy of biliary tract infection.
